TheraRadar
Data updated: Jul 17, 2026

VANTIN (cefpodoxime proxetil) · Pfizer

Infectious Disease Approved 1992-08-07

VANTIN is FDA-approved to treat 5 conditions (same as CEFPODOXIME PROXETIL).

Source: FDA Label
Jump to: Indications Approvals Trials Competitors Safety Patents
6
Indications
--
Phase 3 Trials
33
Years on Market

Details

Status
Discontinued
First Approved
1992-08-07
Routes
ORAL
Dosage Forms
TABLET, FOR SUSPENSION

Companies

Pfizer
Active Ingredient: CEFPODOXIME PROXETIL

VANTIN Approval History

1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
66 FDA actions from 1992 to 2013 · 5 indication expansions
Jun 2013 SUPPL
Label · Labeling
FDA Letter Label
Jun 2007 SUPPL
Label · Labeling
FDA Letter Label
Jun 2004 SUPPL
Label · Labeling
FDA Letter Label

What VANTIN Treats

5 indications

VANTIN is approved for 5 conditions since its original approval in 1992. These indications span multiple therapeutic areas including oncology, immunology, and more.

Same approved indications as CEFPODOXIME PROXETIL (same active ingredient).

Source: FDA Label
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT03491748 CS0282-2017-0001 1010452 Ph 1 completed A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

VANTIN FDA Label Details

Indications & Usage

FDA Label (PDF)

VANTIN is FDA-approved to treat 5 conditions — same approved indications as CEFPODOXIME PROXETIL.

Track VANTIN with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA050674 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.